PPARG and gastric cancer: HSYA treatment increased peroxisome proliferator-activated receptor-γ (PPARγ) and caspase-3 expression in BGC-823 gastric cancer cells, with its inhibitory, apoptotic, and cycle-blocking effects reliant on PPARγ activation (59).